More color on this. Anyone care to weigh in?
Teva Copaxone Patent Reissue Yet Another Defense Strategy
2014-03-20 17:28:17.312 GMT
BI LITI NOAM LITI
Teva asked the U.S. Patent and Trademark Office to consider
reissuing the '808 patent that was invalidated in the Copaxone
litigation against Sandoz, Momenta, Mylan and Natco. Teva has
submitted new claims, amending the indefinite language objected
to by the Federal Circuit. If the patent authorities concur, the
reissue will have the same September 2015 expiry as the original
'808 patent. Teva can then file new litigation against generic
challengers.
Market Data 
Markets 
AI
